Skip to main content

Table 3 Change in symptom domains per standard validated measures by RAD reasons for study drug continuation

From: Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial

   

Groups based on RAD-Q

Groups based on RAD-I

RAD domain

Item

Comparator

N

Mean change (SE)

p-value

N

Mean change (SE)

p-value

Positive Symptoms

Benefits

PANSS Positive

      

Yes

  

215

−10.4 (0.4)

 

206

−10.7 (0.4)

 

No

  

20

−5.2 (1.5)

.001

30

−5.6 (0.8)

.001

Negative Symptoms

Benefits

PANSS Negative

      

Yes

  

111

−7.8 (0.5)

 

110

−7.6 (0.5)

 

No

  

90

−2.9 (0.5)

.001

112

−3.5 (0.5)

.001

Mood Items

Benefits

PANSS Anxiety/Depression

      

Yes

  

113

−5.7 (0.4)

 

139

−5.5 (0.3)

 

No

  

97

−3.4 (0.4)

.001

83

−3.3 (0.4)

.001

Cognition Items

Benefits

PANSS Cognition

      

Yes

  

108

−7.7 (0.5)

 

131

−7.1 (0.5)

 

No

  

102

−4.0 (0.4)

.001

91

−4.1 (0.4)

.001

Functioning Items

Benefits

QLS Total

      

Yes

  

137

25.1 (2.0)

 

141

23.4 (2.0)

 

No

  

81

7.3 (2.0)

.001

88

8.5 (2.0)

.001

Social Support Items

Family/Friends Support

QLS Interpersonal Relations

      

Yes

  

43

7.0 (1.4)

 

45

7.6 (1.3)

 

No

  

181

8.1 (0.8)

.512

186

7.7 (0.8)

.975

  1. Yes = “Somewhat” to “Primary Reason” was chosen; No = “Not a Reason” was chosen; N = number of patients; PANSS = Positive and Negative Syndrome Scale; QLS = Heinrich Carpenter Quality of Life Scale; RAD = Reasons for Antipsychotic Discontinuation/Continuation; SE = standard error.